Literature DB >> 383331

Immunological changes observed in indeterminate and lepromatous leprosy patients and Mitsuda-negative contacts after the inoculation of a mixture of Mycobacterium leprae and BCG.

J Convit, N Aranzazu, M Pinardi, M Ulrich.   

Abstract

This investigation was carried out to study the possibility of eliciting favourable immunological changes in small groups of Mitsuda-negative patients with indeterminate leprosy, lepromatous patients who were bacteriologically negative after prolonged treatment with sulphones, and in Mitsuda-negative contacts by means of stimulation with a mixture of autoclaved tissues from Mycobacterium leprae-infected armadillos and living BCG. A radical change was observed in the specific immunological activity of the indeterminate group, all of whom initially had occasional bacilli in cutaneous nerves in biopsies taken from hypopigmented spots, and in the persistently Mitsuda-negative contacts. The 48 hr and 30 day reactions to lepromin, the 48 hr reaction to supernatant antigen from lepromin, the test for bacillary clearence and in vitro lymphocyte transformation (LTT) to M. leprae from human and armadillo lesions all became positive. Of the lepromatous patients studied, only one became positive to all the criteria mentioned above. In the others, the 48 hr reaction to supernatant antigen, the LTT to antigen from a humn source, and the clearance test remained negative, while the Fernandez and Mitsuda reactions became positive. These results are discussed in terms of the possible use of this stimulation procedure in the prevention and immunotherapy of leprosy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 383331      PMCID: PMC1537730     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  10 in total

1.  Immunologic significance of the cell wall of mycobacteria.

Authors:  E RIBI; C L LARSON; R LIST; W WICHT
Journal:  Proc Soc Exp Biol Med       Date:  1958-06

2.  Enhancement of resistance to murine leprosy by BCG plus specific antigen.

Authors:  J M FERNANDEZ; J H HANKS
Journal:  Int J Lepr       Date:  1956 Jan-Mar

3.  Altered immunologic reactions in sarcoidosis.

Authors:  M SONES; H L ISRAEL
Journal:  Ann Intern Med       Date:  1954-02       Impact factor: 25.391

4.  Elimination of Mycobacterium leprae subsequent to local in vivo activation of macrophages in lepromatous leprosy by other mycobacteria.

Authors:  J Convit; M E Pinardi; G Rodríguez Ochoa; M Ulrich; J L Avila; M Goihman
Journal:  Clin Exp Immunol       Date:  1974-06       Impact factor: 4.330

5.  Immunological basis for depression of cellular immunity and the delayed allergic response in patients with lepromatous leprosy.

Authors:  J L Turk; M F Waters
Journal:  Lancet       Date:  1968-08-24       Impact factor: 79.321

6.  Lymphocyte transformation with phytomitogens in leprosy.

Authors:  M Ulrich; B de Salas; J Convit
Journal:  Int J Lepr Other Mycobact Dis       Date:  1972 Jan-Mar

7.  Some considerations regarding the immunology of leprosy.

Authors:  J Convit; M E Pinardi; F A Rojas
Journal:  Int J Lepr Other Mycobact Dis       Date:  1971 Apr-Jun

8.  Cross reactivities in lepromin.

Authors:  M Goihman-Yahr; S Raffel; R W Ferraresi
Journal:  Int Arch Allergy Appl Immunol       Date:  1969

9.  Specificity of the 48-hour reaction to Mitsuda antigen. Use of a soluble antigen from human and armadillo lepromin.

Authors:  J Convit; M E Pinardi; J L Avila; N Aranzazu
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

10.  A test for the determination of competency in clearing bacilli in leprosy patients.

Authors:  J Convit; J L Avila; M Goihman; M E Pinardi
Journal:  Bull World Health Organ       Date:  1972       Impact factor: 9.408

  10 in total
  11 in total

1.  Serological monitoring of previously treated lepromatous patients during a course of multiple immunotherapy treatments with heat-killed Mycobacterium leprae and BCG.

Authors:  J T Douglas; D S Hirsch; T T Fajardo; L S Guido; P R Klatser
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

2.  Adoptively transferred reactivity to M. leprae in nude mice infected with M. leprae.

Authors:  E J Shannon; S Chehl; C K Job; R C Hastings
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

Review 3.  Leprosy.

Authors:  R C Hastings; T P Gillis; J L Krahenbuhl; S G Franzblau
Journal:  Clin Microbiol Rev       Date:  1988-07       Impact factor: 26.132

Review 4.  Current concepts in the pathogenesis of leprosy. Clinical, pathological, immunological and chemotherapeutic aspects.

Authors:  W M Meyers; A M Marty
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

5.  Enhancement of resistance in Mycobacterium lepraemurium infected C3H mice by treatment with sonicated M. lepraemurium or splenectomy.

Authors:  R Turcotte; J Chaput; S Lemieux
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

6.  Intracellular fate of Mycobacterium leprae in normal and activated mouse macrophages.

Authors:  L D Sibley; S G Franzblau; J L Krahenbuhl
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

7.  Induction of delayed-type hypersensitivity to Mycobacterium leprae in healthy individuals.

Authors:  A H Smelt; R J Rees; F Y Liew
Journal:  Clin Exp Immunol       Date:  1981-06       Impact factor: 4.330

8.  Evidence for the presence of M. leprae reactive T lymphocytes in patients with lepromatous leprosy.

Authors:  I Nath; M Sathish; T Jayaraman; L K Bhutani; A K Sharma
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

9.  Almroth Wright--phagocytosis and opsonization.

Authors:  J L Turk
Journal:  J R Soc Med       Date:  1994-10       Impact factor: 18.000

10.  Autologous tumor lysate/Bacillus Calmette-Guérin immunotherapy as an adjuvant to conventional breast cancer therapy.

Authors:  J Convit; H Montesinos; H Oviedo; G Romero; B Maccarone; E Essenfeld; A Convit; L E Palacios
Journal:  Clin Transl Oncol       Date:  2015-06-16       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.